Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anti-Microbialvior BioteQ CoROCO:6864 -2.28%65 Gross Margin % is 36.54% as of Dec. 2025, which is 22% below its 10-year median of 47.05. GuruFocus rates ROCO:6864 with a GF Score™ of 65/100 and a GF Value™ of NT$25.48 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Anti-Microbialvior BioteQ Co ranks worse than 63.52% on this metric.
Anti-Microbialvior BioteQ Co (ROCO:6864) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Anti-Microbialvior BioteQ Co had a gross margin of 36.54% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Anti-Microbialvior BioteQ Co Gross Margin % Related Terms
Anti-Microbialvior BioteQ Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6864 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Anti-Microbialvior BioteQ Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anti-Microbialvior BioteQ Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anti-Microbialvior BioteQ Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Anti-Microbialvior BioteQ Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Anti-Microbialvior BioteQ Co (ROCO:6864) has a Gross Margin % of 36.54% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Anti-Microbialvior BioteQ Co and its competitors. This is 22% below median its historical median of 47.05. Over the past decade, Anti-Microbialvior BioteQ Co's Gross Margin % has ranged from 23.53 to 97.26. According to the industry distribution chart, Anti-Microbialvior BioteQ Co ranks #465 out of 732 companies in the Biotechnology industry, placing it in the top 63.5%.
Is Anti-Microbialvior BioteQ Co's Gross Margin % too high?
Anti-Microbialvior BioteQ Co's current Gross Margin % of 36.54% is 22% below median its 10-year median of 47.05. Over the past 10 years, this metric has ranged from a low of 23.53 to a high of 97.26. The Biotechnology industry median Gross Margin % is 60.91. Anti-Microbialvior BioteQ Co's value of 36.54% is 40% below this industry median. Based on the distribution chart, Anti-Microbialvior BioteQ Co ranks #465 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anti-Microbialvior BioteQ Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anti-Microbialvior BioteQ Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anti-Microbialvior BioteQ Co ranks #465 out of 732 companies for Gross Margin %. This places Anti-Microbialvior BioteQ Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Anti-Microbialvior BioteQ Co's value of 36.54% is 40% below this benchmark. Historically, Anti-Microbialvior BioteQ Co's own Gross Margin % has ranged from 23.53 to 97.26 over the past decade. While the company's 10-year median is 47.05 vs. the industry median of 60.91, Anti-Microbialvior BioteQ Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anti-Microbialvior BioteQ Co's current Gross Margin % of 36.54% is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Anti-Microbialvior BioteQ Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anti-Microbialvior BioteQ Co's current Gross Margin % is 36.54%, which is 22% below median its own 10-year median of 47.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anti-Microbialvior BioteQ Co stock overvalued right now?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co (ROCO:6864) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.48, compared to a current price of NT$42.90 — trading 68.4% above its estimated fair value. The current Gross Margin % is 36.54%, which is 22% below median its 10-year median of 47.05 and 40% below the Biotechnology industry median of 60.91. Anti-Microbialvior BioteQ Co's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Anti-Microbialvior BioteQ Co (ROCO:6864), the current Gross Margin % is 36.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anti-Microbialvior BioteQ Co (ROCO:6864) Overvalued in 2026?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co stock appears to be overvalued.
The current stock price of NT$42.90 is trading 68.4% above its estimated GF Value™ of NT$25.48.
GuruFocus considers Anti-Microbialvior BioteQ Co to be Significantly Overvalued.
Key valuation signals for ROCO:6864:
Gross Margin %: 36.54% (22% below median its 10-year median of 47.05)
GF Value™: NT$25.48 vs. price of NT$42.90 (68.4% above fair value)
Industry Position: 40% below the Biotechnology median (#465 of 732)
No single metric tells the full story. See the ROCO:6864 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6864 has been successfully added to your 
